Concepedia

Sonja Visscher

SV

Statistics

Publications

6

Citations

476

H-Index

6

Active since

2010

Affiliations

ISA Pharmaceuticals (Netherlands)(Current)

Pharming Group (Netherlands)

Centre Léon Bérard

Institut Gustave Roussy

University of Milan

Sonja Visscher is an author at ISA Pharmaceuticals (Netherlands) specializing in pharmacotherapy, c1 inhibitor, and hereditary angioedema.

ORCID

Publications per year

2010–2024

6

Publications

6

Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema

Bruce L. Zuraw, Marco Cicardi, Robyn J. Levy et al. · Journal of Allergy and Clinical Immunology · 2010 · 218 citations

, , +4

Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

Cornelis J.M. Melief, Marij J.P. Welters, Ignace Vergote et al. · Science Translational Medicine · 2020 · 134 citations · Full text

, , +17

Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study

Dumitru Moldovan, Avner Reshef, J E Fabiani et al. · Clinical & Experimental Allergy · 2012 · 53 citations

, , +11

Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study

Avner Reshef, Dumitru Moldovan, Enikő Mihály et al. · Allergy · 2012 · 43 citations

, , +11

Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).

Caroline Even, Kevin J. Harrington, Erminia Massarelli et al. · Journal of Clinical Oncology · 2024 · 15 citations

, , +13

1–5 of 6